Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Target Cell Response to Hormones01:22

Target Cell Response to Hormones

Hormones intricately bind to receptors on the surface or within target cells, initiating a cascade of cellular responses.
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Regulation of Hormone Secretion01:19

Regulation of Hormone Secretion

Regulation of hormone secretion is a finely tuned orchestration driven by various types of stimuli, encompassing neural, humoral, and hormonal signals. Environmental cues instigate neural stimuli, where action potentials traverse nerve fibers to reach their designated targets. An illustrative scenario is the body's response to stress, wherein the sympathetic nervous system releases epinephrine from the adrenal glands, inducing the well-known 'fight or flight' reaction.
Humoral stimuli,...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
An Overview of the Endocrine System01:10

An Overview of the Endocrine System

The endocrine system, a complex network of glands, orchestrates physiological balance within the body through the production and secretion of hormones. These hormones are chemical messengers in intercellular communication, acting as conduits between the secretory cells and distant target sites. They traverse the circulatory system by being released into the extracellular fluid, and their impact is specific to cells possessing receptors for a particular hormone.
The endocrine system collaborates...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metabolic Response to CDK4/6 Inhibition in ER+ Breast Cancer Creates a Therapeutic Vulnerability in Drug-Tolerant Persister Cells.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2026
Same author

Epithelial-Mesenchymal Transition is Associated with Altered Immune Composition and Cytotoxic Function in Triple-Negative Breast Cancer.

bioRxiv : the preprint server for biology·2025
Same author

Endocrine therapy induces oxidative stress in ER+ breast cancer that sensitizes persister cells to ferroptosis.

bioRxiv : the preprint server for biology·2025
Same author

Combined Radiation and Endocrine Therapies Elicit Benefit in ER+ Breast Cancer.

Cancers·2025
Same author

Reply to: "Comments on the paper 'Extensive epigenomic dysregulation is a hallmark of homologous recombination deficiency in triple-negative breast cancer' by Y. Chen et al."

International journal of cancer·2025
Same author

Quantitative proteomics analysis of triple-negative breast cancers.

NPJ precision oncology·2025
Same journal

Evolving Therapeutic Strategies in Neuroendocrine Neoplasms: A New Era of Personalized Therapies.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Multiple Chapters, One Career: Using Career Development Plans to Find Success and Satisfaction in Academic Oncology Across the Career Spectrum.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Stepping Up With Immune Checkpoint Blockade: More Combinations and Fewer Contraindications.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Optimal Use of Targeted Therapy and Immunotherapy in Early-Stage, Resectable Non-Small Cell Lung Cancer.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Before the Race Even Starts: Early Intervention to Prevent Long-Term Late Effects From Childhood Cancer Therapies.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Artificial Intelligence in Oncology: Practical Applications Across Clinical Care, Scholarship, and Translation.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
See all related articles

Related Experiment Video

Updated: May 11, 2026

Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance
09:48

Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance

Published on: February 17, 2023

Endocrine resistance: what do we know?

Todd W Miller1

  • 1From the Department of Pharmacology and Toxicology and Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH.

American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|May 30, 2013
PubMed
Summary
This summary is machine-generated.

Estrogen receptor-positive breast cancer can become resistant to antiestrogen therapies. Understanding oncogenic signaling pathways is key to developing new treatments for endocrine-resistant breast cancer.

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Experiment Videos

Last Updated: May 11, 2026

Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance
09:48

Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance

Published on: February 17, 2023

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Area of Science:

  • Oncology
  • Molecular Biology
  • Endocrinology

Background:

  • Estrogen receptor-positive (ER+) breast cancer is the most common subtype.
  • Antiestrogen therapies are effective but can lead to endocrine resistance.
  • ER+ breast cancer accounts for a significant number of breast cancer deaths due to its prevalence.

Purpose of the Study:

  • To identify mechanisms driving endocrine resistance in ER+ breast cancer.
  • To explore potential biomarkers for predicting response to targeted therapies.
  • To discuss future strategies for treating endocrine-resistant breast cancer.

Main Methods:

  • Review of experimental evidence on oncogenic signaling pathways.
  • Analysis of pathways implicated in endocrine resistance.
  • Discussion of clinical trial results for combined targeting strategies.

Main Results:

  • Multiple oncogenic signaling pathways, including growth factor receptors (HER2, EGFR, FGFR, IGF-1R/InsR), PI3K/AKT/mTOR, MAPK/ERK, Src, CDK4/CDK6, and ER, are implicated in endocrine resistance.
  • Combined targeting of ER and these pathways shows promising results in clinical trials.
  • Biomarkers for predicting response to targeted agents are under investigation.

Conclusions:

  • Understanding the molecular mechanisms of endocrine resistance is crucial for improving patient outcomes.
  • Targeting both ER and associated oncogenic pathways offers a promising strategy to overcome resistance.
  • Further research is needed to identify optimal treatment strategies for endocrine-resistant breast cancer.